<DOC>
	<DOC>NCT00900627</DOC>
	<brief_summary>The main purpose of this study is to determine if AZD8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer. This study will be conducted in 2 parts: the first part (phase I) will determine a dose of AZD8931 that can be safely administered with paclitaxel chemotherapy. The second part (phase II) will determine the efficacy and safety of AZD8931 in combination with paclitaxel chemotherapy in breast cancer.</brief_summary>
	<brief_title>Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male/ female with solid, malignant tumour which is unresponsive to standard therapies (Phase I). Female patients with advanced breast cancer with low HER2 expression (Phase II) Suitable for paclitaxel chemotherapy Life expectancy more than 12 weeks Inadequate kidney, liver, heart, gastric, lung or eye function Hypersensitive to paclitaxel No symptomatic uncontrolled brain metastases Previous taxane chemotherapy within 12 months (Phase II)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Secondary</keyword>
</DOC>